Evidence map›Paper›PMID 38680163›Full record

ArticleBiology methods & protocols2024

Detection of SARS-CoV-2 B.1.1.529 (Omicron) variant by SYBR Green-based RT-qPCR.

Fadi Abdel-Sater, Rawan Makki, Alia Khalil, Nader Hussein, Nada Borghol, Ziad Abi Khattar, Aline Hamade, Nathalie Khreich, Mahoumd El Homsi, Hussein Kanaan and 10 more

Abstract read
In one paragraph

Article in Biology methods & protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Fadi Abdel-SaterLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Rawan MakkiLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Alia KhalilLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Nader HusseinLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Nada BorgholLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Ziad Abi KhattarLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Aline HamadeLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Nathalie KhreichLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Mahoumd El HomsiLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Hussein KanaanLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Line RaadLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Najwa SkafiLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Fatima Al-NemerLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Zeinab GhandourLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Nabil El-ZeinLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Mhamad Abou-HamdanLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Haidar AklLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Eva HamadeLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Bassam BadranLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.
Kassem HamzeLaboratory of Molecular Biology and Cancer Immunology (COVID-19 Unit), Faculty of science I, Lebanese University, Rafik Hariri Campus, Hadat. Lebanon.ORCID https://orcid.org/0000-0001-6740-4817

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is unceasingly spreading across the globe, and recently a highly transmissible Omicron SARS-CoV-2 variant (B.1.1.529) has been discovered in South Africa and Botswana. Rapid identification of this variant is essential for pandemic assessment and containment. However, variant identification is mainly being performed using expensive and time-consuming genomic sequencing. In this study, we propose an alternative RT-qPCR approach for the detection of the Omicron BA.1 variant using a low-cost and rapid SYBR Green method. We have designed specific primers to confirm the deletion mutations in the spike (S Δ143-145) and the nucleocapsid (N Δ31-33) which are characteristics of this variant. For the evaluation, we used 120 clinical samples from patients with PCR-confirmed SARS-CoV-2 infections, and displaying an S-gene target failure (SGTF) when using TaqPath COVID-19 kit (Thermo Fisher Scientific, Waltham, USA) that included the ORF1ab, S, and N gene targets. Our results showed that all the 120 samples harbored S Δ143-145 and N Δ31-33, which was further confirmed by whole-genome sequencing of 10 samples, thereby validating our SYBR Green-based protocol. This protocol can be easily implemented to rapidly confirm the diagnosis of the Omicron BA.1 variant in COVID-19 patients and prevent its spread among populations, especially in countries with high prevalence of SGTF profile.

Indexed as

B.1.1.529SARS-CoV2 RT-PCRSGTFvariants of concern

Identifiers

PMID38680163
PMCPMC11055497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.